阅读说明：本技术 丁内酯代谢酮i在抗炎中的应用 (Application of butyrolactone metabolic ketone I in anti-inflammation ) 是由 陈宁 刘冰 王淑静 吴健 王冬雪 于 2019-10-15 设计创作，主要内容包括：本发明属于医药技术领域,具体为一种新化合物及其应用,该化合物为丁内酯代谢酮I,所涉及的应用是关于化合物丁内酯代谢酮I用于制备抗炎药物中的应用。丁内酯代谢酮I能够抑制炎症、减少炎症组织渗出液中的MDA含量、降低血清中的NO含量和TNOS、iNOS活性、提高血清中SOD的活性。(The invention belongs to the technical field of medicines, and particularly relates to a novel compound and application thereof. Butyrolactone metabolic ketone I can inhibit inflammation, reduce MDA content in inflammatory tissue exudate, reduce NO content in serum and TNOS and iNOS activities, and improve SOD activity in serum.)

1. The application of the butyrolactone metabolic ketone I in preparing the anti-inflammatory drug is that the structural formula of the butyrolactone metabolic ketone I is shown as the formula I:

2. application of butyrolactone metabolic ketone I in reducing MDA content in inflammatory tissue exudate is provided.

3. Application of butyrolactone metabolic ketone I in reducing NO content in serum and TNOS and iNOS activities.

4. Application of butyrolactone metabolic ketone I in increasing SOD activity in serum is provided.

5. Application of butyrolactone metabolic ketone I in preparing medicine for reducing MDA in inflammatory tissue exudate is provided.

6. Application of butyrolactone metabolic ketone I in preparing medicine for reducing NO content in blood serum.

7. Use of butyrolactone metabolising ketone I in the manufacture of a medicament for reducing TNOS activity in serum.

8. Application of butyrolactone metabolic ketone I in preparing medicine for reducing iNOS activity in serum.

9. Application of butyrolactone metabolic ketone I in preparing food, cosmetic or medicine for increasing SOD activity in serum is provided.

10. Use according to any of claims 1 to 9 of butyrolactone metabolic ketone I in an amount of from 40mg/kg to 80 mg/kg.

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to application of butyrolactone metabolic ketone I in preparation of an anti-inflammatory medicine.

Background

Butyrolactone metabolic ketone I A secondary metabolite butyrrolactone I of aspergillus terreus is orally taken for rats, rat feces are collected, and a new benzophenone compound is obtained by separating the rat feces.

The applicant isolated a novel ketone compound from a rat fecal metabolite of the aspergillus terreus secondary metabolite butyrrolactone I and found its antioxidant effect. The applicant continued research on the properties and efficacy of this compound.

Tests prove that the butyrolactone metabolic ketone I can inhibit inflammation, reduce the MDA content in inflammatory tissue exudate, reduce the NO content in serum, reduce the activities of TNOS and iNOS in serum and improve the activity of SOD in serum, and has a good anti-inflammatory effect.

Disclosure of Invention

The invention aims to provide application of butyrolactone metabolic ketone I in preparation of an anti-inflammatory drug.

The technical scheme of the invention is summarized as follows:

the application of the butyrolactone metabolic ketone I in preparing the anti-inflammatory drug is that the structural formula of the butyrolactone metabolic ketone I is shown as the formula I:

the invention also provides application of the butyrolactone metabolic ketone I in reducing the content of MDA in inflammatory tissue exudate.

The invention also provides application of the butyrolactone metabolic ketone I in reducing the NO content in serum and the activities of TNOS and iNOS.

The invention also provides application of butyrolactone metabolic ketone I in improving SOD activity in serum.

The invention also provides application of the butyrolactone metabolic ketone I in preparation of a medicine for reducing MDA in inflammatory tissue exudate.

The invention also provides application of the butyrolactone metabolic ketone I in preparation of a medicine for reducing the content of NO in serum.

The invention also provides application of the butyrolactone metabolic ketone I in preparation of a medicine for reducing the TNOS activity in serum.

The invention also provides application of the butyrolactone metabolic ketone I in preparation of a medicine for reducing iNOS activity in serum.

The invention also provides application of the butyrolactone metabolic ketone I in preparation of food, cosmetics or medicines for increasing SOD activity in serum.

The dosage of butyrolactone metabolic ketone I in inhibiting inflammation, reducing MDA content in inflammatory tissue exudate, reducing NO content in serum and TNOS and iNOS activities, and increasing SOD activity in serum is 40mg/kg-80 mg/kg.

The invention has the beneficial effects that:

the research proves that the butyrolactone metabolic ketone I has better curative effects on inhibiting inflammation, reducing the MDA content in inflammatory tissue exudate, reducing the NO content in serum and the activities of TNOS and iNOS, and improving the SOD activity in serum.

Detailed Description

The present invention is further described in detail below with reference to examples so that those skilled in the art can practice the invention with reference to the description.